Bioventix has completed a US$1.4 million sell-down of founder’s equity
Bioventix Plc has raised funds through a sell-down of the founder’s equity.
Bioventix was founded in 2003 as a biotechnology company specializing in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics such as clinical blood testing.
Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker in respect of the sell-down of the founder’s equity.
Talk to the deal team
Related deals
Rotem Shani has completed an IPO
Rotem Shani Ltd has completed an IPO to refinance and develop the company.
Learn moreDutch Dental Group has raised new acquisition debt from ING Bank to support its growth strategy
Dutch Dental Group (DDG) has raised a new debt financing package provided by ING Bank, consisting of term loans, an acquisition facility and an RCF.
Learn moreGroupe Voie Lactée has been acquired by Initiative & Finance
JFC Industrie has sold Groupe Voie Lactée to Initiative & Finance.
Learn more